Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niacin controlled release/laropiprant - Merck

Drug Profile

Niacin controlled release/laropiprant - Merck

Alternative Names: Cordaptive; ER niacin/laropiprant; ERN/LRPT - Merck; Extended-release niacin/immediate-release laropiprant; Laropiprant/ER niacin; Laropiprant/extended-release niacin; Laropiprant/nicotinic acid; MK-0524A; MK-524A; Nicotinic acid/laropiprant; Pelzont; Tredaptive; Tredaptive Extended-release tab; Trevaclyn

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Merck Sharp & Dohme
  • Class Antihyperlipidaemics; Indoles; Nicotinic acids; Small molecules
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists; Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Dyslipidaemias; Hypercholesterolaemia
  • Discontinued Atherosclerosis

Most Recent Events

  • 09 Mar 2013 Withdrawn for Dyslipidaemias in Hong Kong (PO)
  • 09 Mar 2013 Withdrawn for Dyslipidaemias in Israel (PO)
  • 09 Mar 2013 Withdrawn for Dyslipidaemias in New Zealand (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top